| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Vincenza Conteduca | Q64495656 |
| P2093 | author name string | Gerhardt Attard | |
| Daniel Wetterskog | |||
| Anuradha Jayaram | |||
| Enrique González-Billalabeitia | |||
| P2860 | cites work | Development of a second-generation antiandrogen for treatment of advanced prostate cancer | Q24605577 |
| Digital PCR | Q24685020 | ||
| The influence of subclonal resistance mutations on targeted cancer therapy | Q26781693 | ||
| Liquid biopsies: genotyping circulating tumor DNA | Q27010159 | ||
| Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | Q27851474 | ||
| Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer | Q27852185 | ||
| A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. | Q27852366 | ||
| Integrative clinical genomics of advanced prostate cancer | Q27853170 | ||
| DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer | Q27853235 | ||
| Overcoming mutation-based resistance to antiandrogens with rational drug design | Q28044590 | ||
| Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA | Q28239638 | ||
| Development of personalized tumor biomarkers using massively parallel sequencing | Q28278819 | ||
| Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing | Q28280303 | ||
| Circulating mutant DNA to assess tumor dynamics | Q28289337 | ||
| Cancer statistics, 2016 | Q29547383 | ||
| Clonal evolution in cancer | Q29547696 | ||
| The mutational landscape of lethal castration-resistant prostate cancer | Q29614634 | ||
| Analysis of circulating tumor DNA to monitor metastatic breast cancer | Q29614797 | ||
| Androgen receptor in prostate cancer | Q29616454 | ||
| Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA | Q29620083 | ||
| Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. | Q30831010 | ||
| Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer | Q33235187 | ||
| Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. | Q33663019 | ||
| Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. | Q33944203 | ||
| Fetal DNA in maternal plasma: biology and diagnostic applications | Q34098822 | ||
| Cell-free nucleic acids as biomarkers in cancer patients | Q34184393 | ||
| From prenatal genomic diagnosis to fetal personalized medicine: progress and challenges | Q34286705 | ||
| Integrated digital error suppression for improved detection of circulating tumor DNA | Q34520008 | ||
| Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. | Q34557699 | ||
| The Molecular Taxonomy of Primary Prostate Cancer | Q34674332 | ||
| Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors | Q35178389 | ||
| Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients | Q35212779 | ||
| The evolutionary history of lethal metastatic prostate cancer | Q35548366 | ||
| Tumor clone dynamics in lethal prostate cancer | Q35575930 | ||
| Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer | Q35584698 | ||
| Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. | Q35603660 | ||
| Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. | Q50075397 | ||
| Genomic hallmarks of localized, non-indolent prostate cancer. | Q50211176 | ||
| Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. | Q51068972 | ||
| Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker Test. | Q52611937 | ||
| Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. | Q53787362 | ||
| Plasma AR and abiraterone-resistant prostate cancer. | Q53810482 | ||
| Maternal Plasma DNA Sequencing Reveals the Genome-Wide Genetic and Mutational Profile of the Fetus | Q56937251 | ||
| Presence of fetal DNA in maternal plasma and serum | Q57075132 | ||
| Prostate cancer | Q57121731 | ||
| Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells | Q73202210 | ||
| Circulating nucleic acids in plasma and serum: recent developments | Q79362831 | ||
| Cell-free DNA levels as a prognostic marker in acute myocardial infarction | Q79362883 | ||
| Short-term treadmill running as a model for studying cell-free DNA kinetics in vivo | Q83378166 | ||
| Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease | Q84589922 | ||
| Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making | Q88817029 | ||
| Non-random fragmentation patterns in circulating cell-free DNA reflect epigenetic regulation | Q36392412 | ||
| Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin | Q36468959 | ||
| Circulating nucleic acids (CNAs) and cancer--a survey | Q36669780 | ||
| Androgen receptor and prostate cancer | Q36734752 | ||
| Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer | Q37302524 | ||
| Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer | Q37550588 | ||
| Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. | Q37590738 | ||
| SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer | Q37595372 | ||
| Molecular characterization and clinical utility of circulating tumor cells in the treatment of prostate cancer | Q38214294 | ||
| The emerging role of extracellular vesicles as biomarkers for urogenital cancers. | Q38268801 | ||
| Quantification of free circulating DNA as a diagnostic marker in lung cancer | Q38350044 | ||
| A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. | Q38664856 | ||
| Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. | Q38706310 | ||
| Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance | Q38722705 | ||
| Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer | Q38768101 | ||
| Strategies to design clinical studies to identify predictive biomarkers in cancer research. | Q38770451 | ||
| Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study | Q38804089 | ||
| Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. | Q38815964 | ||
| Tracking the Evolution of Non-Small-Cell Lung Cancer | Q38818761 | ||
| Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity | Q38919780 | ||
| Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. | Q38991113 | ||
| A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer | Q39144862 | ||
| Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer | Q39541646 | ||
| Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer. | Q39766437 | ||
| Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors | Q40224466 | ||
| Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns | Q40372810 | ||
| Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. | Q40374954 | ||
| Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer | Q41344070 | ||
| Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer | Q41354811 | ||
| Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer. | Q41868457 | ||
| Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer | Q42704874 | ||
| DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. | Q43540280 | ||
| Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. | Q46086455 | ||
| Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer | Q46209531 | ||
| Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance | Q46354502 | ||
| Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification | Q46827358 | ||
| Clinical applications of urinary cell-free DNA in cancer: current insights and promising future | Q47108198 | ||
| Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. | Q47562402 | ||
| Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. | Q47759846 | ||
| Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer | Q49790156 | ||
| Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide | Q50030814 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| cell-free tumour DNA | Q19596321 | ||
| prostate neoplasm | Q56014511 | ||
| P304 | page(s) | 195-205 | |
| P577 | publication date | 2018-11-09 | |
| 2019-05-01 | |||
| P1433 | published in | Prostate Cancer and Prostatic Diseases | Q2108326 |
| P1476 | title | Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test | |
| P478 | volume | 22 |
| Q89866401 | Androgen receptor variant-driven prostate cancer II: advances in clinical investigation |
| Q92852968 | Bioinformatics Analysis for Circulating Cell-Free DNA in Cancer |
| Q97569103 | Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer |
Search more.